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Abstract
Background: The thymidine kinase (tk) mutagenesis assay is often utilized to determine the
frequency of herpes simplex virus (HSV) replication-mediated mutations. Using this assay, clinical
and laboratory HSV-2 isolates were shown to have a 10- to 80-fold higher frequency of
spontaneous mutations compared to HSV-1.
Methods: A panel of HSV-1 and HSV-2, along with polymerase-recombinant viruses expressing
type 2 polymerase (Pol) within a type 1 genome, were evaluated using the tk and non-HSV DNA
mutagenesis assays to measure HSV replication-dependent errors and determine whether the
higher mutation frequency of HSV-2 is a distinct property of type 2 polymerases.
Results: Although HSV-2 have mutation frequencies higher than HSV-1 in the tk assay, these
errors are assay-specific. In fact, wild type HSV-1 and the antimutator HSV-1 PAAr5 exhibited a 2–
4 fold higher frequency than HSV-2 in the non-HSV DNA mutatagenesis assay. Furthermore,
regardless of assay, HSV-1 recombinants expressing HSV-2 Pol had error rates similar to HSV-1,
whereas the high mutator virus, HSV-2 6757, consistently showed signficant errors. Additionally,
plasmid DNA containing the HSV-2 tk gene, but not type 1 tk or LacZ DNA, was shown to form
an anisomorphic DNA stucture.
Conclusions: This study suggests that the Pol is not solely responsible for the virus-type specific
differences in mutation frequency. Accordingly, it is possible that (a) mutations may be modulated
by other viral polypeptides cooperating with Pol, and (b) the localized secondary structure of the
viral genome may partially account for the apparently enhanced error frequency of HSV-2.
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The replicative polymerase of herpes simplex virus (HSV)
is comprised of catalytic (Pol) and processivity subunits
(UL42) [9,11]. HSV Pol is responsible, in concert with
other viral proteins, for regulating the fidelity of DNA rep-
lication by selecting the correct nucleotides for incorpora-
tion and by proofreading or editing mispaired nucleotides
[20]. The Pol subunit contains intrinsic 3'-5' exonuclease
activity [14–16] and the N-terminal region of the
polypeptide encoding this function is highly conserved in
other polymerases, containing three segments referred to
as Exo motifs [3,26].
Thymidine kinase polypeptide (TK) is required for the ac-
tivation of some antiviral nucleoside analogs e.g. acyclovir
(ACV) and penciclovir (PCV), in order to inhibit viral
DNA replication. HSV with TK mutations may impair ac-
tivation of these drugs and confer a drug-resistant pheno-
type. The natural phenomenon of spontaneous mutation,
which occurs in the absence of drug selection, results in
the accumulation of approximately six to eight TK-defi-
cient variants per 104 plaque-forming viruses in virus pop-
ulations that have never been exposed to selective
pressure [6,10,12]. Furthermore, HSV-2 clinical isolates
were shown to have a higher frequency of spontaneous
mutations resistant to ACV and PCV, approximately 30-
fold, compared to HSV-1 isolates, and the majority of
these mutations are in tk. Consistent with this observa-
tion, HSV-2 strains also exhibited approximately a 20- to
80-fold higher spontaneous mutation rate to cidofovir
(HPMPC), an inhibitor of HSV Pol, resistance compared
with HSV-1 [21]. Therefore, these naturally-occuring mu-
tations are not unique to tk and TK substrates as detected
with antiviral agents ACV and PCV, but were extended
with the direct Pol inhibitor, HPMPC, to other loci, most
likely pol.
Since mutations within the viral pol gene have been previ-
ously shown to affect spontaneous viral mutation rates
[10], the higher frequency of errors associated with type 2
viruses may be an inherent property of the type 2 Pol. To
assess the direct contribution of polymerases from virus
types 1 and 2 to mutation frequency, recombinant HSV
expressing a type 2 Pol within a type 1 viral genome were
generated by marker transfer and examined along with a
panel of other HSV isolates in two mutagenesis assays.
Materials and methods
Cell lines, compounds and viruses
Vero (ATCC, passage 15–20), MRC-5 (ATCC, passage 12–
15) and PolB3 (kind gift of D. Coen, Harvard University,
Boston MA) cell lines were grown in Dulbecco's Modified
Eagle's Medium (DMEM) supplemented with 10% fetal
calf serum (FCS) and incubated at 37°C, 5%CO2. PolB3
represents a Vero cell line constitutively expressing the
HSV-1 Pol [17]. PCV was synthesized at SmithKline Bee-
cham Pharmaceuticals. ACV used in these studies was ob-
tained from Sigma (St. Louis, MO). For cell culture assays,
10 mg/ml stock solutions were prepared in dimethyl sul-
phoxide (DMSO) and stored at -20°C. Working dilutions
were prepared in assay medium immediately before use as
described below. HSV-1 strain SC16 (wild type laboratory
virus), HSV-2 SB5 (wild type laboratory virus), HSV-2
6652 (wild type clinical virus), HSV-2 83D (wild type clin-
ical virus), HSV-2 6757 (high error mutant clinical virus)
were described previously [21] and the HSV-1 PAAr5 (an-
timutator laboratory virus) utilized in this study was a
kind gift of D. Coen (Harvard University, Boston, MA)
[10]. HP66 (HSV-1 genome containing a LacZ insertion
within the pol coding region) viral DNA was kindly pro-
vided by D. Coen (Harvard University, Boston, MA) [17].
HP66 viral stocks were prepared by transfecting HP66 vi-
ral DNA into PolB3 cells, which allow for virus propaga-
tion by expressing the viral polymerase.
In vitro susceptibility assays
The tk mutagenesis assay was performed in MRC5 and
Vero cells as described previously [10,21]. The proportion
of resistant virus referred to as mutation frequency or error
frequency throughout this study was calculated as follows:
(titer in the presence of drug) / (titer in the absence of
drug) × 100.
Construction of recombinant viruses
Marker transfer experiments involved co-transfection of
HSV-2 pol coding region (HSV-2 SB5, HSV-2 83D, HSV-2
6652 and HSV-2 6757 described in [21]) with HP66 viral
DNA into Vero cells. Recombinant virus was plaque puri-
fied to homogeneity in the presence of X-Gal. The pol cod-
ing region from the recombinant viruses was confirmed to
be identical to their respective parental virus pol sequences
by terminator cycle sequencing using an automated mod-
el 377 DNA sequencer (Perkin Elmer, Applied Biosys-
tems).
Virus growth analysis
To compare the ability of parental viruses and recom-
binant viruses to replicate in Vero cells with that of the
wild type HSV-2 SB5 strain, 3 × 105 Vero cells were infect-
ed with each virus at a multiplicity of infection of 5 PFU
per cell. Virus progeny were harvested at different time
points and titered on Vero cells. All viruses yielded similar
PFU/ml (data not shown).
Plasmid construction
A non-HSV gene template (pSV110) was constructed by
taking the plasmid pSVβgal (Promega) and inserting the
HSV-1 origin of replication (oriS) SmaI fragment [5]. The
plasmid pTK1 contains HSV-1 SC16 sequence coordinates
45,055–48,634 subcloned into the HindIII / EcoRI site ofPage 2 of 8
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SB5 sequence coordinates 44,469–48,184 subcloned into
the HindIII / EcoRI site of pUC19. The plasmid pLacZ
contains the LacZ coding region from pSVβgal subcloned
into the HindIII / EcoRI site of pUC19.
Transient replication/rescue assay
Vero cells were seeded at 3 × 105 cells per 2 mL well in a
six well plate and incubated overnight at 37°C. The fol-
lowing day, cells were transfected with 1.5 µg of pSV110
and 1 µg of salmon sperm DNA using Lipofectamine rea-
gent according to the manufacturer's recommendations
(Invitrogen). Following overnight incubation at 37°C, the
medium was removed and virus inoculated at an MOI = 5
in 2 mL volume for 1 h. Following overnight incubation
at 37°C, the cells demonstrated CPE and the infected-cell
monolayer was rinsed twice with 1X phosphate buffered
saline. Next, cell monolayers were lysed by scraping into
1.0 mL of lysis buffer (0.6% SDS, 0.01 M EDTA pH 7.5)
per well. The infected cell lysate was adjusted to a final
concentration of 1 M NaCl, inverted 10X and stored at
4°C overnight. The samples were centrifuged at 14,000
rpm for 10 minutes at 4°C and the supernatant was col-
lected, treated with 100 µg/ml RNAse at 37°C for one
hour. Following that incubation, 100 µg/mL Proteinase K
was added and samples were incubated at 50°C for 2
hours. After several phenol-chloroform extractions, the
DNA was precipitated, centrifuged at 14,000 rpm for 10
minutes at 4°C and the pellets resuspended in 50 µl water
and incubated at 37°C for 2 hours. To remove non-repli-
cated templates, 2.5 µg of infected cell DNA was digested
with DpnI and precipitated, centrifuged at 14,000 rpm for
10 minutes at 4°C and resuspended in 20 µl dH2O. One-
fourth of the DpnI-treated DNA was transformed into
DH5α cells (recombination-deficient bacterial cells; Invit-
rogen). The transformation mix was plated onto several
LB-AMP plates containing Xgal and isopropyl β-D thioga-
lactoside (IPTG). The number of blue colonies (indicating
no mutation in β galactosidase gene) and white colonies
(indicating mutation within β galactosidase gene or pro-
moter) were determined. An average of 300,000 colonies
were recovered from three independent experiments for
each virus infection. Two control samples were included
in each experiment to normalize for mutations induced
by transfection or superinfection processes. For the trans-
fection control, pSV110 was transfected into Vero cells,
mock-infected and directly transformed into bacteria for
blue/white colony screening. For the superinfection con-
trol, pSV110 was transfected into Vero cells, superinfected
with HP66 Pol-mutant virus (which is unable to replicate)
and transformed into bacteria for blue/white colony
screening. For the controls, both DpnI and non-DpnI
treated samples were anlayzed. The values in Table 2 are
presented as mutation frequency which is (number of
white colonies from test sample/number of blue colonies
from test sample) - (number of white colonies from HP66
superinfection sample/number of blue colonies from
HP66 superinfection sample) × 100.
S1 nuclease digestion assay
Supercoiled plasmids (5 µg) were treated with 3 units S1
nuclease or mock-treated, in S1 nuclease buffer (Invitro-
gen) containing 100 mM final concentration of NaCl, for
5 min at 37°C. Reactions were stopped by performing two
phenol, and two phenol-chloroform extractions. DNA
was precipitated with ethanol, centrifuged and resuspend-
ed in dH2O for digestion with restriction enzymes as indi-
cated. Restriction digested samples were electrophoresed
on a 0.8% agarose gel and stained with ethidium bromide
for visualization. Two separate plasmid purifications were
utilized for this study, with similar results.
Results
Pol-recombinant viruses
HSV-2 pol (SB5, 83D, 6652 and 6757 described in [21]) or
HSV-1 pol (SC16 and PAAr5) coding regions were co-
transfected with replication defective HP66 viral DNA
containing a LacZ insertion within pol[17] into Vero cells
to generate recombinant viruses. Recombinant viruses
were successfully obtained for all pols except wild type
HSV-1 SC16 and the low error rate or antimutator HSV-1
PAAr5 [10]. The pol-recombinant viruses were plaque-pu-
rified and the pol genes completely sequenced along with
those of their parental viruses to confirm the recombina-
tion event. Three of the HSV-2 viruses, HSV-2 SB5, HSV-2
6652 and HSV-2 83D, had pol sequences consistent with
wild type isolates found in GeneBank and were recently
characterized [21].
Table 2: Mutation frequency in non-HSV DNA.
Virusa Mutation Frequencyb (%)
HSV-2 SB5 1.7, 2.0, 1.7c
HSV-2 SB5PR 2.0, 1.8, 2.1
HSV-2 6652 0.7, 0.9, 1.1
HSV-2 6652PR 1.3, 1.0, 1.5
HSV-2 83D 0.8, 1.1, 1.0
HSV-2 83D PR 1.6, 1.2, 1.8
HSV-2 6757 4.1, 3.4, 4.9
HSV-2 6757PR 1.2, 1.1, 1.1
HSV-1 SC16 2.6, 2.2, 2.1
PAAr5 3.5, 3.6, 4.1
aVirus labeled PR represents pol-recombinant virus. bMutation fre-
quency = (number of white colonies for test sample/ number of blue 
colonies for test sample) - (number of white colonies in control sam-
ple/number of blue colonies in control sample) × 100. cThree inde-
pendent experiments were performed, with data presented from 
experiment 1, 2 and 3, respectively.Page 3 of 8
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700-fold higher error rate than HSV-1 SC16 by the tk mu-
tagenesis assay previously [21], was found to contain
three mutations compared to the other HSV-2 pols, with
one change residing in region VII which is shared among
diverse DNA polymerases (Fig. 1). No amino acid changes
were identified within the proofreading (Exo) domains.
The high frequency of errors generated by HSV-2 6757 did
not appear to preclude its ability to replicate efficiently in
culture. In fact, no significant differences in the growth
curve of parental and recombinant viruses in Vero cells
(compared to wild type HSV-2 SB5) were apparent (data
not shown).
tk mutagenesis assay
The proportions of virus resistant to ACV or PCV, which
arise during amplification of virus stocks in the absence of
drug selection, were measured by the method described
by Hall et al. [10]. Plating efficiency assays were per-
formed in MRC-5 cells at 3 µg/ml ACV, which is 10-times
higher than the average IC50 for HSV-1 SVC16, and at 8
µg/ml ACV, which is 10-times higher than the average
IC50 for the panel of HSV-2 viruses. Notably, whereas the
four HSV-2 parental viruses had spontaneous mutation
frequencies significantly higher than HSV-1 isolates (Ta-
ble 1), the frequency of errors from pol-recombinant virus-
es expressing an HSV-2 Pol in an HSV-1 background were
Figure 1
Schematic of HSV pol locus and conserved regions. Regions I through VII, similar among α-like DNA polymerases, are indicated
as boxed areas with amino acid residue boundaries. Region VII purported to function in substrate recognition and binding is
shown with the amino acid sequences from various DNA polymerases. The following polymerases are represented: HSV [28];
varicella-zoster virus (VZV) [7]; Epstein-Barr virus (EBV) [2]; Vaccinia [8]; Saccharomyces cerevisiae Pol δ (CDC2) [4]; human
Pol α [27]; S. cerevisiae Pol α (Yeast Pol 1) [18]; T4 DNA polymerase (T4) [25]. The changes identified in HSV-2 6757 DNA
polymerase are indicated. The numbers adjacent to the various polymerase indicate the residue number for the beginning of
shared exonuclease domain VII.Page 4 of 8
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5 cells. In fact, three of the type 2 pol-recombinant viruses,
SB5PR, 6652PR and 83DPR, had error rates equal to or
slightly lower than HSV-1 SC16 (0.05%). Results were
similar for plating efficiency with PCV (data not shown).
In this assay, the HSV-2 Pol does not appear to be solely
responsible for the difference in drug-resistant spontane-
ous tk mutations observed between HSV-1 and HSV-2
strains.
Interestingly, unlike the other pol-recombinant viruses,
6757PR, containing the pol coding region from the super-
mutator clinical isolate HSV-2 6757, retained a high spon-
taneous mutation frequency. This recombinant virus
showed a sixty-fold increase in mutation frequency com-
pared to HSV-1 SC16 (Table 1). This increase in errors is
most likely the direct result of the mutations identified
within the pol coding region and suggests that this virus
may indeed possess a Pol defect in replication fidelity. The
fact that the 6757PR mutation frequency was 3–5%,
whilst parental HSV-2 6757 was 20–28%, implicates the
target/template or other viral proteins in modulating
spontaneous mutations.
Drug-independent mutation frequency using non-HSV 
DNA
To eliminate any contribution of drug selection or tk gene
template on the spontaneous mutation frequency in the tk
mutagenesis assay, non drug-selected HSV replication-de-
pendent mutations within an unrelated prokaryotic gene
were measured using a LacZ shuttle plasmid assay. This as-
say employed transfection of a plasmid containing the
230 bp SmaI fragment of oris, the HSV origin of replica-
tion, and a LacZ reporter gene, into Vero cells. This plas-
mid was confirmed to generate DpnI-resistant progeny in
Vero cells upon superinfection with the wild type HSV-1
and HSV-2 (data not shown). After superinfection, DpnI-
resistant (non-methylated; replicated) plasmid DNA was
rescued in E. coli. In the presence of X-Gal, bacterial colo-
nies which turn blue do not contain mutations in the LacZ
promoter or LacZ coding region. However, colonies re-
maining white contain mutations to impair LacZ expres-
sion.
Mutations can be introduced during replication by the vi-
ral proteins or also by the mutagenic processes of transfec-
tion and viral infection. Since the process of transfection
is often mutagenic, pSV110 was transfected into Vero
cells, mock-infected and rescued into bacteria to deter-
mine background frequency of mutation from the experi-
mental process. Transfection was found to confer a
mutation frequency less than 0.002% (6 white colonies in
over 300,000 total colonies) after analyzing non-DpnI
treated samples. No colonies were recovered when treat-
ing the rescued DNA with DpnI. Moreover, to ensure that
viral replication, and not simply the process of viral infec-
tion, is responsible for the mutations in a rescued plas-
mid, a control transfection-superinfection was performed
using the pol mutant, HP66, which is unable to replicate.
The mutation frequency contributed directly from the
process of viral infection was 0.12% (335 in over 280,000
colonies) after analyzing non-DpnI treated samples. Less
than 25 colonies were recovered when treating the rescued
DNA with DpnI. The data presented in Table 2 was nor-
malized by subtracting the mutation frequency for HP66
infection (0.12 %).
The relative mutation frequency for the panel of viruses
tested in the non-HSV DNA mutagenesis assay are pre-
sented in Table 2. Consistent with recent data from
Hwang et al. [13], PAAr5 showed a minor increase in mu-
tation frequency, compared with wild type HSV-1 and
HSV-2 (Table 2). The presence of an antimutator pheno-
type with this viral polymerase in the tk mutagenesis assay
was not apparent when using the non-HSV DNA muta-
genesis assay, and therefore phenotype-labelling may be
dependent upon both the assay method and/or the target
gene. Moreover, the panel of wild type HSV-2 viruses and
the PR viruses in this LacZ phenotypic assay had mutation
frequencies similar or below that of wild type HSV-1
SC16. Thus, the high proportion of errors associated with
HSV-2 viruses appears specific to the tk mutagenesis assay.
HSV-2 6757, although not 6757PR, conferred a slightly
higher proportion of mutations in non-HSV DNA in the
plasmid assay, than wild type HSV-1 and HSV-2, consist-
ent with a mutator phenotype. Sequencing of the Pol en-
Table 1: Percent of ACVr mutants from tk mutagenesis assaya.
%ACVr
Virusb 3 µg/ml 8 µg/ml
HSV-2 SB5 0.8 0.7
HSV-2 SB5PR 0.06 0.04
HSV-2 6652 1.0 0.8
HSV-2 6652PR 0.04 0.01
HSV-2 83D 0.7 0.5
HSV-2 83D PR 0.18 0.06
HSV-2 6757 28 20
HSV-2 6757PR 5.0 3.0
HSV-1 SC16 0.06 0.05
PAAr5 0.001 0.0006
a The proportion of resistant virus was calculated as follows: (titer in 
the presence of drug) / (titer in the absence of drug) × 100. b Virus 
labeled PR represents pol-recombinant virus.Page 5 of 8
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changes which may contribute to the higher error rate, al-
though the direct relationship of these individual muta-
tions within the pol coding region to decreased Pol fidelity
has not been confirmed (Figure 1). It remains unclear
whether a conserved residue change (Lys to Arg at 943) in
region VII, a motif purported to participate in the recogni-
tion of the PPi and nucleotide substrates [27], or whether
one or more of the other three residue changes identified
in HSV-2 6757 pol cooperate to affect mutation frequency.
Anisomorphic DNA conformations
Reiterated sequence elements are often observed to form
an unwound S1 nuclease-sensitive DNA conformation,
termed anisomorphic or left-handed DNA, when present
in negatively supercoiled plasmids [22,24]. Nuclease-sen-
sitive secondary structures within the HSV origin of repli-
cation are believed to be recognized by the viral origin
binding protein, and mutations that reduce this complex
formation in vitro also reduce viral replication, thereby in-
dicating that localized torsional strain may occur during
viral DNA replication [1]. The tk mutagenesis assay meas-
ures replication-dependent mutation frequency within
the tk gene, whereas the non-HSV DNA mutagenesis assay
measures errors within a bacterial LacZ gene. Three pUC-
based plasmids were examined for the potential to form
S1 nuclease sensitive structures: pTK1 which contains a
3.6 Kb HSV-1 DNA fragment including the tk coding re-
gion, pTK2 containing a 3.7 Kb HSV-2 DNA fragment in-
cluding the tk coding region, and pLacZ which contains
the 3.4 Kb LacZ coding region. These negatively super-
coiled plasmids were treated with S1 nuclease or mock-
treated for 5 min. After removal of the nuclease, the plas-
mids were linearized with HindIII. Figure 2 shows that
treatment of pTK1 and pLacZ with S1 nuclease did not al-
ter the restriction enzyme profile, suggesting that in this
assay, the formation of S1 nuclease-sensitive structures
was below the level of detection (Fig. 2, lanes 3–6). How-
ever, pTK2 was readily digested with S1 nuclease, which
resulted in the appearance of four novel bands suggesting
two potential nuclease-hypersensitive sites (Fig. 2, lane 2).
Additional restriction mapping studies suggest that the
hypersensitive regions are within the viral DNA fragment,
and not in pUC DNA (data not shown).
Discussion
The tk mutagenesis assay has been utilized by ourselves
and others [10,13] to determine both frequency and spec-
trum of mutations in the HSV tk gene following selection
for drug resistance. In this study, we have extended the
findings of previous work [13] by using pol-recombinant
viruses to examine mutation frequency in HSV. Specifical-
ly, this study evaluated the contribution of type 2
polymerase to mutation frequency when measured by the
tk mutagenesis and non-HSV DNA mutagenesis assays.
The control viruses, HSV-2 6757 and HSV-1 PAAr5, dem-
onstrated mutator or antimutator phenotypes, respective-
ly, in thetk mutagenesis assay, but not in the non-HSV
DNA mutagenesis assay. Thus, classification of a pol gene
as mutator (HSV-2 6757) or antimutator (PAAr5) is not a
general characteristic, but is likely dependent upon the as-
say method and target gene. This observation is consistent
with the recent report of high mutation frequency within
the SupF gene upon replication by PAAr5 [13].
Since the control viruses described above functioned as
expected in the tk mutagenesis assay, recombinant viruses
expressing the HSV-2 polymerase within an HSV-1 ge-
nome were also examined. Interestingly, three wild type
HSV-2 polymerases (6652, 83D and SB5) showed muta-
tion frequencies similar to HSV-1 SC16, rather than their
parental virus, when placed within an HSV-1 genome.
Only HSV-2 6757 maintained a high error rate (60-fold)
over that of HSV-1 SC16, when placed within an HSV-1
genome. However, the mutation frequency of this recom-
binant virus (HSV-2 6757PR) was not completely pene-
trant when compared to the parental HSV-2 6757 virus,
which showed a 400-fold higher percent of resistant mu-
tants compared to HSV-1 SC16.
An important distinguishing factor between the tk muta-
genesis and LacZ test systems is the use of antiviral selec-
tors to measure mutation frequency. Silent mutations
within the tk gene that do not impair susceptibility to an-
tiviral agents, or mutations resulting in lethality of the vi-
rus, would escape detection as a mutation in the tk
Figure 2
S1 nuclease sensitivity assay. Supercoiled plasmids pTK2
(lanes 1–2), pTK1 (lanes 3–4) and pLacZ (lanes 5–6) were
treated with or without S1 nuclease prior to linearization
with HindIII. DNA fragments were electrophoresed on a
0.8% agarose gel and visualized by staining with ethidium bro-
mide. Treatment with or without S1 nuclease is indicated at
the top of the gel. S1 nuclease cleavage products and a DNA
ladder (in Kb) are indicated.Page 6 of 8
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replicated is unique between these systems and this could
contribute to the differences in mutation frequency be-
tween assay systems. The demonstration of S1 nuclease-
sensitive sites within the type 2 viral genome overlapping
the tk coding region, and the absence of such sites in the
type 1 viral genome, suggest that local topology may be
different between these HSV-1 and HSV-2. Although the
potential contribution of this supercoiling-induced phe-
nomenon to modulate mutation frequency during viral
replication is unclear, it could partially explain why the
type 2 polymerases confer a high mutation frequency to
HSV-2 genomes and a low mutation frequency when
placed within an HSV-1 genome. Changes in local topol-
ogy could contribute to polymerase slippage and the in-
corporation of errors.
The inability of type 2 viruses to confer a higher mutation
rate than type 1 viruses in the non-HSV DNA mutagenesis
assay is consistent with the absence of S1 nuclease hyper-
sensitive sites in the LacZ gene fragment. Furthermore, the
HSV-2 tk sequence used herein contained almost 69% G-
C content, compared to the HSV-1 tk which has 65% of
bases as G or C. Melting temperature alone may not con-
tribute to the difference in S1 nuclease sensitivity. Howev-
er, alignment of the tk sequences showed that the type 2
gene had at least eight distinct stretches containing be-
tween 7 and 13 G-C bases, whereas the overlapping region
in the type 1 tk had four or less G-C bases. This differential
in more extensive G-C rich regions supports the observa-
tions reported herein.
The data presented herein clearly demonstrate that
polymerase alone may not account for the high mutation
frequency associated with type 2 viruses in the tk muta-
genesis assay. In addition to the potential impact of target
sequence and secondary structure topology on mutation
frequency, other viral replicative proteins including Pol
accessory protein, TK, dUTPase, and uracil-DNA glycosy-
lase may cooperate with Pol to modulate polymerase re-




We thank D. Coen for generous gift of reagents; R. Boon for support from 
GlaxoSmithKline Consumer Healthcare; and H. Cowley and K. Esser for 
support.
References
1. Aslani A, Simonsson S, Elias P: A novel conformation of the her-
pes simplex virus origin of DNA replication recognized by
the origin binding protein. J. Biol. Chem. 2000, 275:5880-5887
2. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ,
Hatfull G, Hudson GS, Satchwell SC, Seguin C, Tuffnell PS, Barrell BG:
DNA sequence and expression of the B95-8 Epstein-Barr vi-
rus genome. Nature. 1984, 310:207-211
3. Bernad A, Blanco L, Lazaro JM, Martin G, Salas M: A conserved 3'-
5' exonuclease active site in prokaryotic and eukaryotic
DNA polymerases. Cell. 1989, 59:219-228
4. Boulet A, Simon M, Faye G, Bauer A, Burgers PMJ: Structure and
function of the Saccharomyces cerevisiae CDC2 gene encod-
ing the large subunit of DNA polymerase III. EMBO J. 1989,
8:1849-1854
5. Challberg MD: A method for identifying the viral genes re-
quired for herpesvirus DNA replication. Proc. Natl. Acad. Sci. U.
S. A. 1986, 83:9094-9098
6. Dasgupta UB, Summers WC: Ultraviolet reactivation of herpes
simplex virus is mutagenic and inducible in mammalian cells.
Proc. Natl. Acad. Sci. U. S. A. 1978, 75:2378-2381
7. Davison AJ, Scott JE: The complete DNA sequence of varicella-
zoster virus. J. Gen. Virol. 1986, 67:1759-1816
8. Earl PL, Jones EV, Moss B: Homology between DNA polymeras-
es of poxviruses, herpesviruses, and adenoviruses: nucle-
otide sequence of the vaccinia virus DNA polymerase gene.
Proc. Natl. Acad. Sci. USA 1986, 83:3659-3663
9. Gottlieb J, Marcy AI, Coen DM, Challberg MD: The herpes simplex
virus type 1 UL42 gene product: a subunit of DNA polymer-
ase that functions to increase processivity. J. Virol. 1990,
64:5976-5987
10. Hall JD, Coen DM, Fisher BL, Weisslitz M, Randall S, Almy RE, Gelep
PT, Schaffer PA: Generation of genetic diversity in herpes sim-
plex virus: an antimutator phenotype maps to the DNA
polymerase locus. Virology 1984, 132:26-37
11. Hernandez TR, Lehman IR: Functional interaction between the
herpes simplex-1 DNA polymerase and UL42 protein. J. Biol.
Chem. 1990, 265:11227-11232
12. Hwang CC, Chen HH: An altered spectrum of herpes simplex
virus mutations mediated by an antimutator DNA polymer-
ase. Gene 1995, 152:191-193
13. Hwang YT, Liu BY, Hong CY, Shillitoe EJ, Hwang CC: Effects of ex-
onuclease activity and nucleotide selectivity of the herpes
simplex virus DNA polymerase on the fidelity of DNA repli-
cation in vivo. J. Virol. 1999, 73:5326-5332
14. Knopf CW: Properties of herpes simplex virus DNA polymer-
ase and characterization of its associated exonuclease activ-
ity. Eur. J. Biochem. 1979, 98:231-244
15. Knopf CW, Weisshart K: Comparison of exonucleolytic activi-
ties of herpes simplex virus type-1 DNA polymerase and
DNase. Eur. J. Biochem. 1990, 191:263-273
16. Marcy AI, Olivo PD, Challberg MD, Coen DM: Enzymatic activi-
ties of overexpressed herpes simplex virus DNA polymerase
purified from recombinant baculovirus-infected insect cells.
Nucleic Acids Res. 1990, 18:1207-1215
17. Marcy AI, Yager DR, Coen DM: Isolation and characterization of
herpes simplex virus mutants containing engineered muta-
tions at the DNA polymerase locus. J. Virol. 1990, 64:2208-2216
18. Pizzagalli A, Valsasnini P, Plevani P, Lucchini G: DNA polymerase I
gene of Saccharomyces cerevisiae: nucleotide sequence,
mapping of a temperature-sensitive mutation and protein
homology with other DNA polymerases. Proc. Natl. Acad. Sci.
USA 1988, 85:3772-3776
19. Pyles RB, Thompson RL: Mutations in accessory DNA replicat-
ing functions alter the relative mutation frequency of herpes
simplex virus type 1 strains in cultured murine cells. J. Virol.
1994, 68:4514-4524
20. Roberts JD, Kunkel TA: Eukaryotic DNA replication fidelity,. In
DNA replication in eukaryotic cells.  (Edited by: ML DePamphilis) Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, New York. 1996, 217-
247
21. Sarisky RT, Nguyen TT, Duffy KE, Wittrock RJ, Leary JJ: Difference
in incidence of spontaneous mutations distinct between her-
pes simplex virus types 1 and 2. Antimicrob. Agents Chemother.
2000, 44:1524-1529
22. Sarisky RT, Weber PC: Role of anisomorphic DNA conforma-
tions in the negative regulation of a herpes simplex virus
type 1 promoter. Virology. 1994, 204:569-579
23. Shillitoe EJ, Zhang S, Wang G, Hwang CBC: Functions and pro-
teins of herpes simplex virus type-1 that are involved in rais-
ing the mutation frequency of inefcted cells. Virus Res. 1993,
27:239-251Page 7 of 8
(page number not for citation purposes)
BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/724. Singleton CK, Klysik J, Stirdivant SM, Wells RD: Left-handed Z-
DNA is induced by supercoiling in physiological ionic condi-
tions. Nature. 1982, 299:312-316
25. Spicer EK, Rush J, Fung C, Reha-Krantz LJ, Karam JD, Konigsberg
WH: Primary structure of T4 DNA polymerase. Evolutionary
relatedness to eucaryotic and other procaryotic DNA
polymerases. J. Biol. Chem. 1988, 263:7478-7486
26. Weisshart K, Kuo AA, Hwang CC, Kumura C, Coen DM: Structural
and functional organization of herpes simplex virus DNA
polymerase investigated by limited proteolysis. J. Biol. Chem
1994, 269:22788-22796
27. Wong SW, Wahl AF, Yuan PM, Arai N, Pearson BE, Arai KI, Korn D,
Hunkapiller MW, Wang TSF: Human DNA polymerase alpha
gene expression is cell proliferation dependent and its pri-
mary structure is similar to both prokaryotic and eukaryotic
replicative DNA polymerases. EMBO J. 1988, 7:37-47
28. Xiong X, Yang H, Westland CE, Zou R, Gibbs CS: In vitro evalua-
tion of epatitis B virus polymerase mutations associated with
famciclovir resistance. Hepatology. 2000, 31:219-224
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/2/7/prepub
Publish with BioMed Central  and  every 
scientist can read your work free of charge
"BioMedcentral will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Paul Nurse, Director-General, Imperial Cancer Research Fund
Publish with BMC and your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours - you keep the copyright
editorial@biomedcentral.com
Submit your manuscript here:
http://www.biomedcentral.com/manuscript/
BioMedcentral.comPage 8 of 8
(page number not for citation purposes)
